← Back to headlines
Novartis Acquires Allergy-Drug Developer Excellergy for Up to $2 Billion
Pharmaceutical company Novartis is expanding its allergy medication business with the acquisition of the unlisted US biotech firm Excellergy in a deal valued at up to $2 billion, marking its second multi-billion dollar acquisition in a week and betting on a next-generation allergy treatment.
27 Mar, 11:43 — 27 Mar, 12:33
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (56/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
bloomberg
Right2
Right (2)
wsjdie-presse
Far R
Geographic diversity— 2 regions9/34
US3Austria1
Sources
Showing 2 of 4 sources
wsjHigh141d ago
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion - WSJ
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion WSJ
Read full article →cnbcMostly Factual141d ago
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
Read full article →Coverage Timeline
First report: die-presse · 27 Mar, 07:00|Full coverage: 4 · 6h|Window: 6h
Left-leaningCenterRight-leaning
